RARα Agonists for Aortic Valve Calcification Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for aortic valve calcification, particularly calcific aortic valve disease (CAVD), lack targeted medical therapies to prevent, slow down, or treat fibrocalcific AVS, and bioprosthetic valve degeneration due to tissue calcification, with retinoid data limited and vitamin A intake potentially promoting heart valve calcification.
Innovation Solution
Utilizing retinoic acid receptor alpha (RARα) agonists to reverse, prevent, or delay aortic valve calcification through methods of primary and secondary prevention, including treatment of calcific aortic valve disease and bioprosthetic valve calcification, with local delivery via bioprosthetic valves.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If bioprosthetic valves are used to treat aortic valve stenosis, then valve replacement is achieved, but structural valve deterioration due to tissue calcification occurs long-term
Solution Approach 1:
The patent applies preliminary action by incorporating RARα agonist into the bioprosthetic valve before implantation, which prevents calcification from occurring in the first place rather than treating it after it develops. The agonist is delivered locally to the valve tissue at the time of implantation, creating a preventive effect that addresses the root cause of structural valve deterioration before it can progress.
Solution Approach 2:
The patent uses RARα agonist as an intermediary substance that mediates between the bioprosthetic valve material and the calcification process. This chemical mediator binds to retinoic acid receptors in valvular interstitial cells, blocking the calcification pathway and preventing the direct interaction between the valve tissue and calcific deposits, thereby extending valve longevity.
2Object-affected harmful factors
If retinoid acid is used to inhibit osteoblastic mineralization, then calcification is reduced, but data on aortic valve calcification is limited and dietary intake may promote calcification
Solution Approach 1:
The patent applies local quality by targeting specifically the RARα receptor subtype in valvular interstitial cells, rather than using general retinoid therapy. This localized approach focuses the therapeutic effect precisely where it is needed - in the valve tissue - while using a specific mechanism (RARα activation) that has been shown to inhibit calcification without the ambiguous effects of dietary retinoids.
Solution Approach 2:
The patent replaces the uncertain dietary retinoid approach with a direct pharmacological intervention using RARα agonists. Instead of relying on complex dietary intake that has ambiguous effects, the patent uses a well-defined molecular mechanism where the agonist binds to RARα receptors, activating a specific signaling pathway that inhibits calcification with predictable and reliable effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
RARα agonists effectively inhibit calcification and osteoblast-like phenotypes in valvular interstitial cells, reducing calcium deposits and delaying or preventing aortic valve stenosis, thereby prolonging bioprosthetic valve function.
Implementation Method 1
retinoic acid receptor alpha (RARα) agonists for use in a method for reversing, preventing or delaying calcification of the aortic valve
Data Source
Figure 1A~1B
Figure 2A~2B
Figure 2C~3A
AI summary
Aortic valve calcification is a condition in which calcium deposits form on the aortic valve in the heart. These deposits can cause narrowing at the opening of the aortic valve. This narrowing can become severe enough to reduce blood flow through the aortic valve - a condition called aortic valve stenosis. The inventors have shown that retinoic acid decreases calcification and osteoblast-like phenotype in valvular interstitial cells (VICs). More particularly, RARα activation reduces calcification and osteoblast-like phenotype in VIC. On the contrary, ALDH1A1 inhibition increases calcification and osteoblast-like phenotype in VIC. Thus the results prompt to consider that use or retinoic acid receptor (RAR) agonists would be suitable for the reversing, preventing or delaying calcification of the aortic valve.